REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 21, 2012--
Codexis, Inc. (NASDAQ:CDXS), a developer of industrial enzymes to enable
the cost-advantaged production of biofuels, bio-based chemicals and
pharmaceutical intermediates, today announced that Joe Sarret has
resigned as Senior Vice President and Chief Business Officer, effective
August 3, 2012.
“We thank Joe for his many contributions to Codexis,” said John Nicols,
President and Chief Executive Officer of Codexis. “Under Joe’s
leadership, Codexis has established successful collaborations with
several leading global companies. We are grateful for his leadership,
and we all wish Joe the best in his future endeavors.”
“The Codexis team and its core technology platform are a powerful
combination. I am confident that Codexis products and technology will
continue to make a significant impact in our target markets,” said Dr.
Sarret. “I wish my Codexis colleagues every success.”
About Codexis, Inc.
Codexis, Inc. is a developer of industrial enzymes to enable the
cost-advantaged production of biofuels, bio-based chemicals and
pharmaceutical intermediates. Codexis' product lines include CodeXyme™
Cellulase Enzymes and CodeXol™ Detergent Alcohol. Partners and customers
include global leaders such as Shell, Merck and Pfizer. For more
information, see www.codexis.com.
This press release contains forward-looking statements relating to the
impact of Codexis’ products and technology on its target markets. You
should not place undue reliance on these forward-looking statements
because they involve known and unknown risks, uncertainties and other
factors that are, in some cases, beyond our control and could materially
affect actual results. Factors that could materially affect actual
results include our need for substantial additional capital in the
future in order to expand our business, our dependence on our
collaborators and various challenges to the feasability of the
production and commercialization of biofuels and bio-based chemicals
derived from cellulose. Additional factors that could materially affect
actual results can be found in Codexis’ Quarterly Report on Form 10-Q
for the period ended March 31, 2012 filed with the Securities and
Exchange Commission on May 10, 2012, including under the caption “Risk
Factors.” Codexis expressly disclaims any intent or obligation to update
these forward-looking statements, except as required by law.
Source: Codexis, Inc.
Wes Bolsen, 650-421-2356